Additionally, engineering T cells to express anti‐senescent factors, such as telomerase or inhibitors of p16 and p21, targets intrinsic aging pathways, reducing senescence and boosting anti‐tumor activity (Janelle et al. 2021; Amor et al. 2020; Akincilar et al. 2016). The gene discussed is CDKN2A; the disease is neoplasm.